絞り込み

16636

広告

Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.

著者 Thase ME , Youakim JM , Skuban A , Hobart M , Augustine C , Zhang P , McQuade RD , Carson WH , Nyilas M , Sanchez R , Eriksson H
J Clin Psychiatry.2015 Aug 4 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (25view , 0users)
To assess the efficacy, tolerability, and safety of brexpiprazole as adjunctive therapy to antidepressant treatments (ADTs) in adults with major depressive disorder (as defined by DSM-IV-TR criteria) and inadequate response to ADTs.
PMID: 26301701 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード